Why markets already priced in a vaccine approval, stellar gains from AIM stocks in 2020, retail’s latest challenge and dealing with NS&I’s punishing rate cuts

episode

AJ Bell Money & Markets not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Trump Welcomes Xi, US Unveils Two-Month China Truce Extension, More 8 min · 24 Sep 2026 · Bloomberg News Now

“The world is a casino”: polling, politics & Palantir w/ Galen Druke 1h 33m · 24 Sep 2026 · Pod Save the UK

Donald Is Done For; All Hell Breaks Loose After Devastating Attacks 29 min · 24 Sep 2026 · IHIP News

Michael Petrillo | Melbourne City Director of Football (24.09.26) 4 min · 24 Sep 2026 · Whateley

"Saving Super Rugby" 1h 12m · 24 Sep 2026 · The Agenda

S26 Ep15: WCN Presents: [Jenn Holman] There is a Softer Life 47 min · 24 Sep 2026 · Something Was Wrong

Report any issue

Source

Recorded03 Dec 2020

Publisherfeed.podbean.com ↗

Handlerec:12382240

Show notes

The UK’s status as the first country in the world to approve Pfizer’s Covid vaccine failed to move stock markets on the day of the news. Listen to the podcast to find out why markets reacted in this way. Tom Sieber from Shares magazine joins the show to discuss the reasons why the AIM market has done nearly as well as the US S&P 500 in 2020 and significantly outperformed large cap UK stocks in the FTSE 100. The podcast looks at the large rate cuts on NS&I accounts and what savers can do to improve their situation. And the team also debate the latest in the retail sector after Debenham’s struggles and Arcadia going into administration. Presented by AJ Bell’s Dan Coatsworth and Laith Khalaf

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in